Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBIZ7H)

Drug Name
ICT-107 Drug Info
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Phase 3 [1]
Recurrent glioblastoma 2A00.00 Phase 3 [2]
Glioblastoma multiforme 2A00.0 Phase 2 [3]
Cross-matching ID
TTD Drug ID
DMBIZ7H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin 13 receptor alpha-2 (IL13RA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tralokinumab DM6ENSJ Atopic dermatitis EA80 Approved [5]
ABT-308 DM6WN2D Eosinophilic esophagitis DA24.1 Phase 2 [1]
MB-101 DMLA1QD Recurrent glioblastoma 2A00.00 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 13 receptor alpha-2 (IL13RA2) TTMPZ7V I13R2_HUMAN Not Available [4]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics.
5 Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)